{"id":794733,"date":"2024-12-12T17:33:07","date_gmt":"2024-12-12T22:33:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/"},"modified":"2024-12-12T17:33:07","modified_gmt":"2024-12-12T22:33:07","slug":"gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/","title":{"rendered":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer<\/b><\/p>\n<p>FOSTER CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead\u2019s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD.<\/p>\n<p>\nDr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company\u2019s leading virology, oncology and inflammation portfolio and will oversee the company\u2019s global Development and Medical Affairs organizations.<\/p>\n<p>\n\u201cDietmar\u2019s exceptional leadership in global drug development, his track record in delivering transformational therapies, and the breadth and depth of his experience make him an ideal choice as Gilead\u2019s Chief Medical Officer,\u201d said Daniel O\u2019Day, Chairman and Chief Executive Officer of Gilead. \u201cWe are delighted to welcome Dietmar to Gilead at a time when we are poised to extend our leadership in virology and deliver on our significant potential in oncology and inflammation. We look forward to having Dietmar take up his role at the beginning of 2025 as we work to strengthen our impact for patients and communities worldwide.\u201d<\/p>\n<p>\n\u201cI\u2019m honored to join Gilead, an organization I have long admired as an industry leader and one of the world\u2019s most innovative companies, whose transformative therapies have revolutionized the treatment, prevention and cure for some of healthcare\u2019s greatest challenges,\u201d said Dr. Berger. \u201cI am looking forward to working with the talented team at Gilead to continue to advance its promising pipeline and improve health outcomes for communities around the world.\u201d<\/p>\n<p>\nMost recently, Dr. Berger was the Chief Medical Officer and Global Head of Development at Sanofi, where he led development science, strategy and operations across the company\u2019s therapeutic areas of focus. Prior to Sanofi, Dr. Berger served in senior development roles at Atara, Genentech, Bayer and Amgen.<\/p>\n<p>\nAcross a distinguished career in drug development, Dr. Berger has delivered an impressive track record of successful global filings, including multiple cancer treatments, as well as transformative products in other disease areas including immunology, hematology, oncology, and infectious diseases.<\/p>\n<p>\nDr. Berger completed his medical training in Freiburg (Germany), Basel (Switzerland) and Chicago (United States) and holds an MD and PhD from the Albert-Ludwigs University School of Medicine.<\/p>\n<p><b><span class=\"bwuline\">About Gilead Sciences<\/span><\/b><\/p>\n<p>\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.<\/p>\n<p><b><span class=\"bwuline\">Forward-Looking Statements<\/span><\/b><\/p>\n<p>\nThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Gilead may not complete the leadership transition within currently anticipated timelines or at all; challenges that Gilead may encounter in implementing the leadership transition; the ability of Gilead to realize the full potential of its pipeline; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.<\/p>\n<p class=\"bwalignc\"><i>Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.<\/i><\/p>\n<p class=\"bwalignc\"><i>For more information about Gilead, please visit the company\u2019s website at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gilead.com&amp;esheet=54166240&amp;newsitemid=20241212608966&amp;lan=en-US&amp;anchor=www.gilead.com&amp;index=1&amp;md5=a5119073ff22026257a264deb3b25a96\"><i>www.gilead.com<\/i><\/a><i>, follow Gilead on X\/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241212608966\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241212608966\/en\/<\/a><\/span><\/p>\n<p>\nAshleigh Koss, Media<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:public_affairs@gilead.com\">public_affairs@gilead.com<\/a><\/p>\n<p>\nJacquie Ross, Investors<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor_relations@gilead.com\">investor_relations@gilead.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Hospitals Clinical Trials Biotechnology Health Pharmaceutical Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241212608966\/en\/778437\/3\/GCP_Primarylarge_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead\u2019s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company\u2019s leading virology, oncology and inflammation portfolio and will oversee the company\u2019s global Development and Medical Affairs organizations. \u201cDietmar\u2019s exceptional leadership in global drug development, his track &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-794733","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead\u2019s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company\u2019s leading virology, oncology and inflammation portfolio and will oversee the company\u2019s global Development and Medical Affairs organizations. \u201cDietmar\u2019s exceptional leadership in global drug development, his track &hellip; Continue reading &quot;Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-12T22:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer\",\"datePublished\":\"2024-12-12T22:33:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/\"},\"wordCount\":777,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/\",\"name\":\"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-12T22:33:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Market Newsdesk","og_description":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead\u2019s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company\u2019s leading virology, oncology and inflammation portfolio and will oversee the company\u2019s global Development and Medical Affairs organizations. \u201cDietmar\u2019s exceptional leadership in global drug development, his track &hellip; Continue reading \"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-12T22:33:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer","datePublished":"2024-12-12T22:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/"},"wordCount":777,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/","name":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-12T22:33:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241212608966r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=794733"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/794733\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=794733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=794733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=794733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}